The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy.

[1]  W. Sippl,et al.  Development of Alkylated Hydrazides as Highly Potent and Selective Class I Histone Deacetylase Inhibitors with T cell Modulatory Properties. , 2022, Journal of medicinal chemistry.

[2]  X. Wang,et al.  Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors , 2022, BMC Medicine.

[3]  Daria A. Gaykalova,et al.  Entinostat decreases immune suppression to promote anti-tumor responses in a HER2+ breast tumor microenvironment. , 2022, Cancer immunology research.

[4]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[5]  Yuanyuan Wang,et al.  Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy , 2021, Biomarker research.

[6]  T. Lawrence,et al.  The Role of Plasmacytoid Dendritic Cells in Cancers , 2021, Frontiers in Immunology.

[7]  Xianping Lu,et al.  Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas , 2021, Journal of oncology.

[8]  Zhihui Feng,et al.  Valproic acid triggers radiation-induced abscopal effect by modulating the unirradiated tumor immune microenvironment in a rat model of breast cancer. , 2021, Journal of radiation research.

[9]  Tianshu Yang,et al.  Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy , 2021, Clinical epigenetics.

[10]  H. Schiöth,et al.  Recent developments of HDAC inhibitors: Emerging indications and novel molecules , 2021, British journal of clinical pharmacology.

[11]  Kevin Y. Yip,et al.  A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma , 2021, Science Translational Medicine.

[12]  É. Vivier,et al.  Tumor-Infiltrating Natural Killer Cells. , 2020, Cancer discovery.

[13]  K. Wright,et al.  Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. , 2020, Biochemical and biophysical research communications.

[14]  Wei-Guo Zhu,et al.  The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy , 2020, Frontiers in Cell and Developmental Biology.

[15]  E. de Álava,et al.  Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials , 2020, Frontiers in Genetics.

[16]  D. Tarng,et al.  Trichostatin A Alleviates Renal Interstitial Fibrosis Through Modulation of the M2 Macrophage Subpopulation , 2020, International journal of molecular sciences.

[17]  G. Aliev,et al.  Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress. , 2020, Seminars in cancer biology.

[18]  T. Fukumoto,et al.  Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors , 2020, Cancer Immunology, Immunotherapy.

[19]  S. Malarkannan,et al.  Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway , 2020, Oncotarget.

[20]  Mahboubeh Yazdanifar,et al.  γδ T Cells: The Ideal Tool for Cancer Immunotherapy , 2020, Cells.

[21]  A. R. Lee,et al.  HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment , 2020, Journal of Cancer.

[22]  C. Zahnow,et al.  Epigenetic therapy inhibits metastases by disrupting premetastatic niches , 2020, Nature.

[23]  M. Mohty,et al.  Plasmacytoid dendritic cell biology and its role in immune‐mediated diseases , 2020, Clinical & translational immunology.

[24]  Junhong Han,et al.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials , 2019, Signal Transduction and Targeted Therapy.

[25]  Xiaobo Yang,et al.  Trichostatin A modulates the macrophage phenotype by enhancing autophagy to reduce inflammation during polymicrobial sepsis. , 2019, International immunopharmacology.

[26]  S. Cooper,et al.  Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1 , 2019, Cancer Immunology, Immunotherapy.

[27]  R. Bartz,et al.  Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME) , 2019, Journal of Immunotherapy for Cancer.

[28]  Yulun Huang,et al.  Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells , 2019, Journal of Cancer.

[29]  E. Haura,et al.  Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer , 2019, Clinical Cancer Research.

[30]  M. Atkinson,et al.  Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells , 2019, International journal of molecular sciences.

[31]  Xuedong Liu,et al.  Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas , 2019, Cancer Immunology Research.

[32]  H. Nishikawa,et al.  Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? , 2019, Cancer science.

[33]  A. Villagra,et al.  Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy , 2019, International journal of molecular sciences.

[34]  N. Lee,et al.  Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells , 2019, Scientific Reports.

[35]  D. Margolis,et al.  In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals , 2019, AIDS.

[36]  A. Chávez-Blanco,et al.  Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells , 2019, Journal of immunology research.

[37]  M. Hou,et al.  Low-dose chidamide restores immune tolerance in ITP in mice and humans. , 2019, Blood.

[38]  V. Trochon-Joseph,et al.  Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model , 2018, Cancer Immunology, Immunotherapy.

[39]  E. Jaffee,et al.  Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs , 2018, Cancer Immunology Research.

[40]  Chao Yang,et al.  Natural Killer Cells: Development, Maturation, and Clinical Utilization , 2018, Front. Immunol..

[41]  S. Pozzi,et al.  The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease , 2018, International journal of molecular sciences.

[42]  Aaron M Williams,et al.  Protective Effect of Tubastatin A in CLP-Induced Lethal Sepsis , 2018, Inflammation.

[43]  S. Bhat,et al.  Checkpoint Blockade Rescues the Repressive Effect of Histone Deacetylases Inhibitors on γδ T Cell Function , 2018, Front. Immunol..

[44]  W. Ellmeier,et al.  Histone deacetylase function in CD4+ T cells , 2018, Nature Reviews Immunology.

[45]  Tongtong Song,et al.  Trichostatin a Protects Dendritic Cells Against Oxygen-Glucose Deprivation via the SRSF3/PKM2/Glycolytic Pathway , 2018, Front. Pharmacol..

[46]  K. O'Byrne,et al.  Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi , 2018, Front. Oncol..

[47]  G. Marone,et al.  Human mast cells and basophils—How are they similar how are they different? , 2018, Immunological reviews.

[48]  Yan Song,et al.  Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors , 2018, Leukemia.

[49]  David M. Woods,et al.  The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy , 2018, Cancer Immunology, Immunotherapy.

[50]  P. Munster,et al.  HDAC inhibition potentiates immunotherapy in triple negative breast cancer , 2017, Oncotarget.

[51]  J. Dastych,et al.  Differentiation stage‐specific effect of histone deacetylase inhibitors on the expression of RORγT in human lymphocytes , 2017, Journal of leukocyte biology.

[52]  A. Forero,et al.  Modulation of antitumor immunity with histone deacetylase inhibitors. , 2017, Immunotherapy.

[53]  Guocheng Yuan,et al.  Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.

[54]  P. Ordentlich,et al.  Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma , 2017, Clinical Cancer Research.

[55]  E. Lee,et al.  Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro , 2017, Arthritis Research & Therapy.

[56]  A. Letai,et al.  Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages , 2017, Nature.

[57]  W. Alexander,et al.  Haematopoietic stem cells: past, present and future , 2017, Cell Death Discovery.

[58]  G. Nilsson,et al.  Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis , 2016, Oncotarget.

[59]  Ziqian Li,et al.  Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro , 2017, Cancer Immunology, Immunotherapy.

[60]  R. Johnstone,et al.  How do tumor cells respond to HDAC inhibition? , 2016, The FEBS journal.

[61]  J. Karn,et al.  HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function , 2016, Front. Immunol..

[62]  Peter A. Jones,et al.  Epigenetic Determinants of Cancer. , 2016, Cold Spring Harbor perspectives in biology.

[63]  P. Klenerman,et al.  Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function , 2016, PLoS pathogens.

[64]  Min-jie Zhou,et al.  Modulation of Donor-Specific Antibody Production After Organ Transplantation by Valproic Acid: A Histone Deacetylase Inhibitor , 2016, Transplantation.

[65]  F. Sánchez‐Madrid,et al.  HDAC6 regulates the dynamics of lytic granules in cytotoxic T lymphocytes , 2016, Journal of Cell Science.

[66]  L. Boon,et al.  Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma , 2016, Oncoimmunology.

[67]  V. Golubovskaya,et al.  Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy , 2016, Cancers.

[68]  D. S,et al.  Essential role of HDAC6 in the regulation of PD‐L1 in melanoma , 2016, Molecular oncology.

[69]  M. Sweet,et al.  Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages , 2015, Antimicrobial Agents and Chemotherapy.

[70]  P. Casali,et al.  Genome-Wide Analysis Reveals Selective Modulation of microRNAs and mRNAs by Histone Deacetylase Inhibitor in B Cells Induced to Undergo Class-Switch DNA Recombination and Plasma Cell Differentiation , 2015, Front. Immunol..

[71]  M. Brown,et al.  Phase I study evaluating the safety and efficacy of oral panobinostat in combination with radiotherapy or chemoradiotherapy in patients with inoperable stage III non-small-cell lung cancer , 2015, Anti-cancer drugs.

[72]  J. Kinoshita,et al.  Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells. , 2015, Oncology reports.

[73]  David M. Woods,et al.  HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade , 2015, Cancer Immunology Research.

[74]  H. Oberg,et al.  Modulation of human gamma/delta T-cell activation and phenotype by histone deacetylase inhibitors. , 2015, Cellular immunology.

[75]  S. Nimer,et al.  The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis , 2015, Front. Oncol..

[76]  Ø. Bruserud,et al.  Effects of cytarabine on activation of human T cells – cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid , 2015, BMC Pharmacology and Toxicology.

[77]  A. Sewell,et al.  The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy , 2015, Cellular and Molecular Immunology.

[78]  Y. Huang,et al.  Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity , 2015, Oncogene.

[79]  P. Casali,et al.  Histone Deacetylase Inhibitors Upregulate B Cell microRNAs That Silence AID and Blimp-1 Expression for Epigenetic Modulation of Antibody and Autoantibody Responses , 2014, The Journal of Immunology.

[80]  M. Diederich,et al.  Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks. , 2014, Biochemical pharmacology.

[81]  F. Gannon,et al.  Epigenetic regulation in cancer progression , 2014, Cell & Bioscience.

[82]  R. Johnstone,et al.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders , 2015, Nature Reviews Drug Discovery.

[83]  S. Rose-John,et al.  Dendritic cell development requires histone deacetylase activity , 2014, European journal of immunology.

[84]  E. Seto,et al.  Erasers of histone acetylation: the histone deacetylase enzymes. , 2014, Cold Spring Harbor perspectives in biology.

[85]  B. Comin-Anduix,et al.  Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function , 2014, Cancer Immunology Research.

[86]  R. Glauben,et al.  Histone Deacetylase Inhibitors Modulate Interleukin 6-dependent CD4+ T Cell Polarization in Vitro and in Vivo * , 2014, The Journal of Biological Chemistry.

[87]  S. Hehlgans,et al.  The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[88]  M. Lomax,et al.  Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[89]  G. Velmahos,et al.  Novel pharmacologic treatment attenuates septic shock and improves long-term survival. , 2013, Surgery.

[90]  T. Roger,et al.  Epigenetics in sepsis: targeting histone deacetylases. , 2013, International journal of antimicrobial agents.

[91]  Anne-Kathrin Kienzler,et al.  Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid. , 2013, The Journal of allergy and clinical immunology.

[92]  L. Cosmi,et al.  IL-1 and T Helper Immune Responses , 2013, Front. Immunol..

[93]  S. Schleicher,et al.  Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia , 2013, Front. Oncol..

[94]  F. Hamdy,et al.  Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair , 2013, British Journal of Cancer.

[95]  M. Perretti,et al.  Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors , 2012, Cell Death and Differentiation.

[96]  P. Reddy.  Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation. , 2013, Transactions of the American Clinical and Climatological Association.

[97]  Min Zhang,et al.  Butyrate increases IL-23 production by stimulated dendritic cells. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[98]  F. Ferrari,et al.  Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression. , 2012, Experimental hematology.

[99]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[100]  S. Bates,et al.  Low‐dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T‐cell lymphoma lesions , 2012, The British journal of dermatology.

[101]  M. Mohty,et al.  Impact of valproic acid on dendritic cells function. , 2012, Immunobiology.

[102]  Changsheng Du,et al.  The Antiepileptic Drug Valproic Acid Restores T Cell Homeostasis and Ameliorates Pathogenesis of Experimental Autoimmune Encephalomyelitis , 2012, The Journal of Biological Chemistry.

[103]  Jiuhong Kang,et al.  Histone deacetylase inhibition by sodium valproate regulates polarization of macrophage subsets. , 2012, DNA and cell biology.

[104]  M. Caligiuri,et al.  The Histone Deacetylase Inhibitor Valproic Acid Lessens NK Cell Action against Oncolytic Virus-Infected Glioblastoma Cells by Inhibition of STAT5/T-BET Signaling and Generation of Gamma Interferon , 2012, Journal of Virology.

[105]  G. Rabinovich,et al.  Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression , 2012, Journal of leukocyte biology.

[106]  G. Velmahos,et al.  Effect of valproic acid on acute lung injury in a rodent model of intestinal ischemia reperfusion. , 2012, Resuscitation.

[107]  L. Ellis,et al.  Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models , 2012, PloS one.

[108]  M. J. Newman,et al.  Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity , 2012, Cancer Chemotherapy and Pharmacology.

[109]  T. Calandra,et al.  Histone deacetylase inhibitors impair antibacterial defenses of macrophages. , 2011, The Journal of infectious diseases.

[110]  K. Bhalla,et al.  Histone Deacetylase Inhibitor LAQ824 Augments Inflammatory Responses in Macrophages through Transcriptional Regulation of IL-10 , 2011, The Journal of Immunology.

[111]  P. François,et al.  Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. , 2011, Blood.

[112]  C. Seiser,et al.  The biology of HDAC in cancer: the nuclear and epigenetic components. , 2011, Handbook of experimental pharmacology.

[113]  S. Sozzani,et al.  Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. , 2010, Immunobiology.

[114]  W. Hancock,et al.  Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. , 2010, Clinical immunology.

[115]  S. Bates,et al.  Clinical Toxicities of Histone Deacetylase Inhibitors , 2010, Pharmaceuticals.

[116]  C. Geest,et al.  Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation , 2010, Haematologica.

[117]  Kjersti Flatmark,et al.  Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. , 2010, The Lancet. Oncology.

[118]  Calman Prussin,et al.  IgE, mast cells, basophils, and eosinophils. , 2003, The Journal of allergy and clinical immunology.

[119]  I. Adcock,et al.  Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils , 2010, Journal of Inflammation.

[120]  G. Velmahos,et al.  PROTECTIVE EFFECT OF SUBEROYLANILIDE HYDROXAMIC ACID AGAINST LPS-INDUCED SEPTIC SHOCK IN RODENTS , 2009, Shock.

[121]  A. S. Dagtas,et al.  Histone deacetylase inhibitor uses p21(Cip1) to maintain anergy in CD4+ T cells. , 2009, International immunopharmacology.

[122]  Jae Kwon Lee,et al.  Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages , 2009, Archives of pharmacal research.

[123]  S. Chun,et al.  Apicidin, the Histone Deacetylase Inhibitor, Suppresses TH1 Polarization of Murine Bone Marrow-Derived Dendritic Cells , 2009, International journal of immunopathology and pharmacology.

[124]  V Koneti Rao,et al.  Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS). , 2009, Experimental hematology.

[125]  Jee Sun Yang,et al.  Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model , 2008, Experimental & Molecular Medicine.

[126]  E. Seto,et al.  Lysine acetylation: codified crosstalk with other posttranslational modifications. , 2008, Molecular cell.

[127]  C. Dinarello,et al.  Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. , 2008, The Journal of clinical investigation.

[128]  E. Olson,et al.  Deacetylase inhibition promotes the generation and function of regulatory T cells , 2007, Nature Medicine.

[129]  T. Fujimura,et al.  Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. , 2007, Biochemical pharmacology.

[130]  H. Verheul,et al.  Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[131]  Xiang-Jiao Yang,et al.  Metabolism, cytoskeleton and cellular signalling in the grip of protein Nϵ ‐ and O‐acetylation , 2007 .

[132]  S. Sahn,et al.  Valproic Acid–Induced Eosinophilic Pleural Effusion: A Case Report and Review of the Literature , 2007, The American journal of the medical sciences.

[133]  Jindrich Cinatl,et al.  Histone deacetylase inhibitors suppress natural killer cell cytolytic activity , 2007, FEBS letters.

[134]  R. E. Edens,et al.  Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. , 2006, International immunopharmacology.

[135]  S. Boehrer,et al.  Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. , 2005, Cancer research.

[136]  P. Scheipers,et al.  The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses , 2003, BMC Cancer.

[137]  D. Kooy,et al.  Stem and progenitor cells: the premature desertion of rigorous definitions , 2003, Trends in Neurosciences.

[138]  J. Bussel,et al.  Hematologic toxicity of sodium valproate. , 2000, Journal of pediatric hematology/oncology.

[139]  A. Fietta,et al.  Peripheral Benzodiazepine Receptor Expression on Leukocytes and Neutrophil Function during Anticonvulsant Monotherapy , 1998, Pharmacology.

[140]  PETER ALEXANDER,et al.  Cancer Chemotherapy , 1968, Nature.